TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
TCT 2024 - TCTMD.com
Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.
Coronary CTA Reimbursement for US Hospitals to Double in 2025
Nov 8, 2024 · For once, cardiologists find good news in the US Centers for Medicare & Medicaid Services (CMS) annual Hospital Outpatient Prospective Payment System (HOPPS) final rule: in 2025 the payment rate for coronary computed tomography angiography (CCTA) will double.
SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity
Nov 16, 2024 · CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with obesity and heart failure with preserved ejection (HFpEF), results of the SUMMIT trial show.
Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial …
Oct 29, 2024 · WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients treated with PCI after acute myocardial infarction, results from the CLEAR SYNERGY (OASIS 9) trial show.
SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients
Oct 23, 2024 · An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular events than traditional therapy alone in patients with diabetes and established CVD and/or chronic kidney disease (CKD), …
Slides | tctmd.com
Apr 14, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
TCTMD Login - tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
ZENITH: Novel Biologic Reduces Morbidity and Mortality in PAH
Nov 26, 2024 · In patients with advanced pulmonary arterial hypertension (PAH), the addition of the biologic sotatercept-csrk (Winrevair; Merck) to maximum tolerated background therapy reduces the risk of death more than background therapy alone, according to …